Integrase Inhibitor Resistance Notes
Last updated on Sep 15, 2009
| Resistance Matrix | Resistance Mutation Comments | Resistance Mutation Scores |
| Integrase Inhibitor (INI) Resistance Mutations | |||||||||||
| 66 | 92 | 121 | 138 | 140 | 143 | 147 | 148 | 153 | 155 | 263 | |
| Cons | T | E | F | E | G | Y | S | Q | S | N | R |
| Raltegravir† | Q | Y | AK | AS | RCH | G | HRK | HS | |||
| Elvitegravir§ | IAK | Q | Y | AK | AS | G | HRK | Y | HS | K | |
LEGEND INI-resistance mutations selected in persons receiving raltegravir (D Hazuda HIVDRW 2007, I Malet AAC 2008) or elvitegravir (D McColl HIVDRW 2007) are characterized for in vitro susceptibility (G Jones CROI 2007, D McColl HIVDRW 2007, C Ren HIVDRW 2007, M Rowley Prog Med Chem 2008). Mutations in bold red are associated with >5-10 fold decreased susceptibility.
† Other mutations selected in vitro or in vivo by raltegravir include L74M, T97A, V151I, E157Q, G163R, I203M, and S230R/N.
§ Other mutations selected in vitro or in vivo by elvitegravir include the nonpolymorphic mutations H51Y, Q95K, H114Y, P145S, and Q146P (K Shimura JV 2007).
ADDITIONAL MUTATIONS Additional integrase mutations selected by other investigational INIs include the nonpolymorphic mutations T125K, A128T, Q146K, N155S, K160D, and the polymorphic mutations V72I, A154I, V165I, and V201I (M Lataillade AVT 2007).
† Other mutations selected in vitro or in vivo by raltegravir include L74M, T97A, V151I, E157Q, G163R, I203M, and S230R/N.
§ Other mutations selected in vitro or in vivo by elvitegravir include the nonpolymorphic mutations H51Y, Q95K, H114Y, P145S, and Q146P (K Shimura JV 2007).
ADDITIONAL MUTATIONS Additional integrase mutations selected by other investigational INIs include the nonpolymorphic mutations T125K, A128T, Q146K, N155S, K160D, and the polymorphic mutations V72I, A154I, V165I, and V201I (M Lataillade AVT 2007).